Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02524-9
Abstract: Colorectal cancer (CRC) patients with metastatic lesions have low 5-year survival rates. During metastasis, cancer cells often obtain unique characteristics such as epithelial–mesenchymal transition (EMT). Vimentin a biomarker contributes to EMT by changing cell shape… read more here.
Keywords: vimentin immunotherapeutic; colorectal cancer; crc patients; cancer ... See more keywords